Price Alert

Calliditas Therapeutics A... (CALT)

NASDAQ: CALT · Real-Time Price · USD

40.00

-0.04 (-0.10%)

At close: Sep 20, 2024, 10:00 PM

Calliditas Therapeutics AB (publ) Statistics

Share Statistics

Calliditas Therapeutics AB (publ) has 53.69M shares outstanding. The number of shares has increased by -0.64% in one year.

Shares Outstanding	53.69M
Shares Change (YoY)	-0.64%
Shares Change (QoQ)	0%
Owned by Institutions (%)	3.08%
Shares Floating	338.38K
Failed to Deliver (FTD) Shares	200
FTD / Avg. Volume	2.59%

Short Selling Information

The latest short interest is 9.73K, so 0.04% of the outstanding shares have been sold short.

Short Interest	9.73K
Short % of Shares Out	0.04%
Short % of Float	0.05%
Short Ratio (days to cover)	1.09

Valuation Ratios

The PE ratio is -14.92 and the forward PE ratio is 0.46. Calliditas Therapeutics AB (publ)'s PEG ratio is -1.28.

PE Ratio	-14.92
Forward PE	0.46
PS Ratio	5.76
Forward PS	0.4
PB Ratio	20.78
P/FCF Ratio	-15.55
PEG Ratio	-1.28

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Calliditas Therapeutics AB (publ).

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.13, with a Debt / Equity ratio of 2.92.

Current Ratio	3.13
Quick Ratio	3.08
Debt / Equity	2.92
Debt / EBITDA	-2.66
Debt / FCF	-2.19
Interest Coverage	-5.25

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$5.44M
Profits Per Employee	$-2.1M
Employee Count	222
Asset Turnover	0.64
Inventory Turnover	3.77

Taxes

Income Tax	9.17M
Effective Tax Rate	-2.01%

Stock Price Statistics

The stock price has increased by -1.28% in the last 52 weeks. The beta is 1.46, so Calliditas Therapeutics AB (publ)'s price volatility has been higher than the market average.

Beta	1.46
52-Week Price Change	-1.28%
50-Day Moving Average	39.63
200-Day Moving Average	29.36
Relative Strength Index (RSI)	50.54
Average Volume (20 Days)	7,730

Income Statement

In the last 12 months, Calliditas Therapeutics AB (publ) had revenue of 1.21B and earned -466.19M in profits. Earnings per share was -17.38.

Revenue	1.21B
Gross Profit	1.13B
Operating Income	-384.4M
Net Income	-466.19M
EBITDA	-367.8M
EBIT	-383.82M
Earnings Per Share (EPS)	-17.38

Full Income Statement

Balance Sheet

The company has 973.73M in cash and 979.13M in debt, giving a net cash position of -5.4M.

Cash & Cash Equivalents	973.73M
Total Debt	979.13M
Net Cash	-5.4M
Retained Earnings	-2.31B
Total Assets	1.75B
Working Capital	724.69M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -434.65M and capital expenditures -12.79M, giving a free cash flow of -447.44M.

Operating Cash Flow	-434.65M
Capital Expenditures	-12.79M
Free Cash Flow	-447.44M
FCF Per Share	-8.34

Full Cash Flow Statement

Margins

Gross margin is 93.62%, with operating and profit margins of -31.85% and -38.63%.

Gross Margin	93.62%
Operating Margin	-31.85%
Pretax Margin	-37.87%
Profit Margin	-38.63%
EBITDA Margin	-30.48%
EBIT Margin	-31.85%
FCF Margin	-37.07%

Dividends & Yields

CALT does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

Currently there are no analyst rating for CALT.

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	1.51
Piotroski F-Score	2